Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and InVivo Cytokine Administration: Implications for Clinical Therapy

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 8, 2014, Pages 1252-1257

  Miller, Jeffrey S ^a   Rooney, Cliona M ^b   Curtsinger, Julie ^a   McElmurry, Ron ^c   McCullar, Valarie ^a   Verneris, Michael R ^c   Lapteva, Natalia ^b   McKenna, David ^c   Wagner, John E ^c   Blazar, Bruce R ^c   Tolar, Jakub ^c  

^a MMC 366   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Human; Immunotherapy; NK cells; Xenogeneic

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; L SELECTIN; NATURAL KILLER CELL RECEPTOR NKG2A; CYTOKINE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ARTICLE; CELL EXPANSION; CRYOPRESERVATION; EX VIVO STUDY; IMMUNE DEFICIENCY; IN VIVO STUDY; LYMPHOCYTE HOMING; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE; XENOGRAFT;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MICE, INBRED NOD; MICE, SCID; TRANSPLANTATION, HETEROLOGOUS;

EID: 84903995132     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.05.004     Document Type: Article

References (18)

1. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and invivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
2. Geller M.A., Cooley S., Judson P.L., et al. Aphase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13:98-107.
3. Bachanova V., Burns L.J., McKenna D.H., et al. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 2010, 59:1739-1744.
4. Berger C., Berger M., Hackman R.C., et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009, 114:2417-2426.
5. Waldmann T.A., Lugli E., Roederer M., et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 2011, 117:4787-4795.
6. Lapteva N., Durett A.G., Sun J., et al. Large-scale exvivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 2012, 14:1131-1143.
7. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106:376-383.
8. McKenna D.H., Sumstad D., Bostrom N., et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 2007, 47:520-528.
9. Foley B., Cooley S., Verneris M.R., et al. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand invivo in response to recipient CMV antigen. JImmunol 2012, 189:5082-5088.
10. Foley B., Cooley S., Verneris M.R., et al. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood 2011, 118:2784-2792.
11. Romee R., Foley B., Lenvik T., et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013, 121:3599-3608.
12. Bjorkstrom N.K., Riese P., Heuts F., et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010, 116:3853-3864.
13. Lopez-Verges S., Milush J.M., Schwartz B.S., et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci USA 2011, 108:14725-14732.
14. Gattinoni L., Powell D.J., Rosenberg S.A., Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006, 6:383-393.
15. Heemskerk B., Liu K., Dudley M.E., et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther 2008, 19:496-510.
16. Denman C.J., Senyukov V.V., Somanchi S.S., et al. Membrane-Bbound IL-21 promotes sustained exvivo proliferation of human natural killer cells. PloS One 2012, 7:e30264.
17. Berg M., Childs R. Ex-vivo expansion of NK cells: what is the priority-high yield or high purity?. Cytotherapy 2010, 12:969-970.
18. Cooley S., McCullar V., Wangen R., et al. KIR reconstitution is altered by Tcells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005, 106:4370-4376.